$IO Biotech (IOBT.US)$ IO Biotech Presents New Data at AACR 2025 Supporting Dual Mechanism and Immune Activation of Cancer Vaccines IO102-IO103 and IO170 Friday, 25th April at 1:00 pm Preclinical data further support the potential of dual-antigen and TGF-β-directed vaccines to reshape the tumor microenvironment and drive anti-tumor immunity NEW YORK, April 25, 2025 (GLOBE NEWSWIRE) -- IO Biotech (NASDAQ: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulatory, ...
NOTE! 1. NFA (Not Financial Advice!) This is NOT a BUY or SELL advice. 2. Do NOT open position WITHOUT chart confirmation, indicators, momentum. 3. Scale out and secure profits. 4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability. 5. I DO NOT give buy or sell advice 6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (press release; FCF (free cash flow) 7. NEVER be a blind follower. LASTLY, If you...
$IO Biotech (IOBT.US)$IO Biotech Reports 2024 Business Highlights • Preparations for submission of a Biologics License Application (BLA) for Cylembio® (imsapepimut and etimupepimut, adjuvanted) to FDA by year end 2025 remain on track. The trial completed enrollment in December 2023 ahead of plan with 407 patients. The primary endpoint of the pivotal Phase 3 trial is progression free survival (PFS); the rate of PFS events has slowed and th...
$IO Biotech (IOBT.US)$ IO Biotech Announces New Preclinical Data for Additional Pipeline Candidate Presented at the AACR-IO Conference Sunday, 23rd February at 12:07 pm • Findings support the development of a novel peptide vaccine targeting the immunosuppressive effects of Transforming Growth Beta (TGF-β) in solid tumors NEW YORK, Feb. 23, 2025 (GLOBE NEWSWIRE) -- IO Biotech (NASDAQ: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therape...
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.
U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data. U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data.
U.S. Crypto Concept Stocks U.S. Crypto Concept Stocks
Companies involved in the creation, trade, and services of digital forms of money.Displayed third-party logos, brands, or trademark images on screens or web pages are only for identification purposes and remain the property of their respective owners.Displayed third-party logos, brands, or trademark images on screens or web pages are only for identification purposes and remain the property of their respective owners. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S. Crypto Concept Stocks, ranked from highest to lowest based on real-time market data. Companies involved in the creation, trade, and services of digital forms of money.Displayed third-party logos, brands, or trademark images on screens or web pages are only for identification purposes and remain the property of their respective owners.Displayed third-party logos, brands, or trademark images on screens or web pages are only for identification purposes and remain the property of their respective owners. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S. Crypto Concept Stocks, ranked from highest to lowest based on real-time market data.
Following the introduction of China's groundbreaking DeepSeek technology, Wall Street giants have revised their investment outlooks for the Chinese market.
IO Biotech Stock Forum
Breakthrough Cancer Vaccine Data: Dual-Action Treatment Shows Superior Immune Response Against Multiple Tumors
Breakthrough Cancer Vaccine Technology Reveals New Approach to Reprogram Tumor Environment
IO Biotech Presents New Data at AACR 2025 Supporting Dual Mechanism and Immune Activation of Cancer Vaccines IO102-IO103 and IO170
Friday, 25th April at 1:00 pm
Preclinical data further support the potential of dual-antigen and TGF-β-directed vaccines to reshape the tumor microenvironment and drive anti-tumor immunity
NEW YORK, April 25, 2025 (GLOBE NEWSWIRE) -- IO Biotech (NASDAQ: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulatory, ...
Cancer Vaccine Breakthrough: IO Biotech Reveals Phase 3 Melanoma Data at AACR 2025
1. NFA (Not Financial Advice!) This is NOT a BUY or SELL advice.
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (press release; FCF (free cash flow)
7. NEVER be a blind follower.
LASTLY, If you...
•
Preparations for submission of a Biologics License Application (BLA) for Cylembio® (imsapepimut and etimupepimut, adjuvanted) to FDA by year end 2025 remain on track. The trial completed enrollment in December 2023 ahead of plan with 407 patients. The primary endpoint of the pivotal Phase 3 trial is progression free survival (PFS); the rate of PFS events has slowed and th...
Can This New Cancer Vaccine Outsmart Tumors? IO Biotech's Breakthrough Approach
IO Biotech Announces New Preclinical Data for Additional Pipeline Candidate Presented at the AACR-IO Conference
Sunday, 23rd February at 12:07 pm
• Findings support the development of a novel peptide vaccine targeting the immunosuppressive effects of Transforming Growth Beta (TGF-β) in solid tumors
NEW YORK, Feb. 23, 2025 (GLOBE NEWSWIRE) -- IO Biotech (NASDAQ: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therape...
No comment yet